Guanfacine ER (Intuniv) is used to treat attention-deficit hyperactivity disorder (ADHD) in kids ages 6 to 17 years old. Guanfacine ER (Intuniv) isn't a controlled substance and can be an alternative to stimulant-based ADHD medications. Keep in mind that only the extended-release (ER) version of guanfacine, under the brand name Intuniv ER, is approved to treat ADHD. It's taken by mouth, typically once daily. Some common side effects of guanfacine ER (Intuniv) include sleepiness and tiredness. Guanfacine ER (Intuniv) is available as a lower-cost generic medication.
Attention-deficit hyperactivity disorder (ADHD)
Guanfacine ER (Intuniv) is an alpha-2A agonist. It's not clear how guanfacine ER (Intuniv) works to treat attention-deficit hyperactivity disorder (ADHD). It's thought to work by lowering the amount of norepinephrine (a chemical in your brain) in certain parts of your brain that are involved with attention and focus.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):
Not a stimulant, so doesn't have same side effects typically linked to stimulants
Can be taken alone or with other medications for ADHD
Available as a lower-cost generic medication
Only taken once daily
Not a controlled substance since there's no concern for abuse and dependence
Might take several weeks to start working
Not a long-term medication for ADHD
Commonly causes sleepiness and tiredness
Not approved for adults with ADHD
Might not work as well for older children (13 to 17 years old)
Don't crush or cut these tablets. Crushing or cutting the tablets will affect the way this medication works.
Guanfacine ER (Intuniv) can be taken day or night. You can take guanfacine ER (Intuniv) at night if it makes you sleepy.
Avoid taking guanfacine ER (Intuniv) with a high-fat meal. Taking this medication with a high-fat meal will raise the level of medication in your body, which can lead to more side effects, such as sleepiness.
Guanfacine ER (Intuniv) can lower your blood pressure and cause you to feel dizzy, especially when you're getting up from a sitting or lying position. If you need to get up, do so slowly. Your provider might recommend you to check your blood pressure regularly, especially when first starting guanfacine ER (Intuniv), or if your dose changes.
Don't stop guanfacine ER (Intuniv) suddenly because doing so can cause your blood pressure to rise quickly. If you want to stop this medication, talk with your provider. They can help you stop guanfacine ER (Intuniv) safely by lowering your dose slowly over time.
It can cause drowsiness, especially when you first start taking guanfacine ER (Intuniv) or with dose increases, so don't drive until you know how guanfacine ER (Intuniv) affects you.
Guanfacine ER (Intuniv) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Risk factors: Low blood pressure | Heart problems | Kidney problems | History of fainting | Not enough fluids in the body | Taking other medications that lower blood pressure or slow the heart
Guanfacine ER (Intuniv) can lower your blood pressure or heart rate, which can cause you to feel faint and dizzy. You're more likely to experience these side effects when you first start guanfacine ER (Intuniv) and when your provider raises your dose. Because of this, your provider will monitor your blood pressure and heart rate regularly while you're receiving treatment, especially if you're taking blood pressure medications. These side effects should lessen over time. Talk to your healthcare provider if you continue to feel dizzy, tired, or run out of breath easily after using guanfacine ER (Intuniv).
Risk factors: Taking other medications that cause sleepiness | Drinking alcohol
Guanfacine ER (Intuniv) lowers your ability to focus, think, and react for the first few days until you get used to it. Be careful and avoid activities that require you to be alert, such as driving a car or operating machinery, until you know how this medication affects you. Talk to your provider if this doesn't go away after a few days.
Risk factors: High blood pressure
If you have been taking guanfacine ER (Intuniv) for a while, stopping it suddenly can cause a "rebound" effect and lead to high blood pressure. Some other rebound symptoms include headache, fast heart rate, nausea, chest tightness, or feeling nervous or anxious. Try not to miss any doses and don't stop taking guanfacine ER (Intuniv) without talking to your healthcare provider first. They'll help you get off this medication slowly and safely.
Risk factors: History of heart problems
Guanfacine ER (Intuniv) can raise your risk of irregular rhythm. If you're taking medications that affect your heart rhythm, talk to your provider. They might have to make changes to your medications.
The typical starting dose is 1 mg by mouth once daily, either in the morning or evening. Your provider will raise the dose based on your body weight, age, and whether or not you're taking other medications for ADHD. The typical maintenance dose ranges from 2 mg to 7 mg daily.
Attention-deficit hyperactivity disorder (ADHD)
Attention-deficit hyperactivity disorder (ADHD)
Attention-deficit hyperactivity disorder (ADHD) in people ages 6 years and older
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Bernknopf, A., et al. (2011). Guanfacine (Intuniv) for attention-deficit/hyperactivity disorder. American Family Physician.
Giovannitti, Jr., J. A., et al. (2015). Alpha-2 adrenergic receptor agonists: A review of current clinical applications. Anesthesia Progress.
Huss, M., et al. (2018). Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. European Neuropsychopharmacology.
Hussain, L. S., et al. (2023). Physiology, noradrenergic synapse. StatPearls.
Iwanami, A., et al. (2020). Efficacy and safety of guanfacine extended-release in the treatment of attention-deficit/hyperactivity disorder in adults: Results of a randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry.
Post, R. E., et al. (2012). Diagnosis and management of attention-deficit/hyperactivity disorder in adults. American Family Physician.
Strawn, J. R., et al. (2017). Extended release guanfacine in pediatric anxiety disorders: A pilot, randomized, placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology.
Takeda Pharmaceuticals America, Inc. (2022). INTUNIV- guanfacine tablet, extended release; INTUNIV- guanfacine kit [package insert]. DailyMed.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.